NASDAQ:LOXO - Loxo Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$138.87 -1.13 (-0.81 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$138.87
Today's Range$136.84 - $142.3950
52-Week Range$75.78 - $208.95
Volume284,915 shs
Average Volume344,708 shs
Market Capitalization$4.25 billion
P/E Ratio-26.15
Dividend YieldN/A
Beta2.21
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Receive LOXO News and Ratings via Email

Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOXO
Previous Symbol
CUSIPN/A
Phone203-653-3880

Debt

Debt-to-Equity RatioN/A
Current Ratio3.62
Quick Ratio3.62

Price-To-Earnings

Trailing P/E Ratio-26.15
Forward P/E Ratio-59.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.30 million
Price / Sales199.57
Cash FlowN/A
Price / Cash FlowN/A
Book Value$12.63 per share
Price / Book11.00

Profitability

EPS (Most Recent Fiscal Year)($5.31)
Net Income$-148,870,000.00
Net Margins-43.49%
Return on Equity-16.42%
Return on Assets-8.66%

Miscellaneous

Employees59
Outstanding Shares30,610,000
Market Cap$4.25 billion
OptionableOptionable

Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology Inc (NASDAQ:LOXO) posted its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.24. The biopharmaceutical company earned $42.47 million during the quarter, compared to analyst estimates of $38.55 million. Loxo Oncology had a negative net margin of 43.49% and a negative return on equity of 16.42%. During the same period last year, the company earned ($2.45) EPS. View Loxo Oncology's Earnings History.

When is Loxo Oncology's next earnings date?

Loxo Oncology is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Loxo Oncology.

What price target have analysts set for LOXO?

15 Wall Street analysts have issued 12-month price targets for Loxo Oncology's shares. Their forecasts range from $132.00 to $235.00. On average, they anticipate Loxo Oncology's stock price to reach $188.2727 in the next twelve months. This suggests a possible upside of 35.6% from the stock's current price. View Analyst Price Targets for Loxo Oncology.

What is the consensus analysts' recommendation for Loxo Oncology?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Loxo Oncology in the last year. There are currently 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:
  • 1. JMP Securities analysts commented, "We view the success of larotrectinib as a crucial step in the paradigm shift we see occurring in the treatment landscape for oncology toward biomarker-driven drug development. Further, we consider the FDA’s support of larotrectinib, which has benefited from expedited development in the U.S. due to its breakthrough therapy status and accelerated approval pathways, as signaling the agency’s commitment to ushering in a new era of targeted medicines in oncology." (11/29/2018)
  • 2. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (11/16/2018)
  • 3. Citigroup Inc analysts commented, "Enbrel treats rheumatoid arthritis and related diseases and is a major contributor to Amgen’s sales and growth. We currently estimate that Enbrel sales in the psoriatic arthritis (PsA) setting account for 13% of total Enbrel sales in 2018. Enbrel’s overall market penetration likely will moderate due to completion from biosimilars outside the US and potentially in the US. We anticipate Enbrel sales to decline by approximately 6% per year from 2017-2022, but will still account for 12% of sales by 2022. However, these data presented today at ACR in PA could lead to increased adoption in the setting and provide upside to our outlook." (10/24/2018)

Has Loxo Oncology been receiving favorable news coverage?

Media coverage about LOXO stock has trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Loxo Oncology earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:
  • Dr. Joshua H. Bilenker, Founder, Pres, CEO & Director (Age 46)
  • Ms. Jennifer Burstein, Sr. VP of Fin. (Age 46)
  • Mr. Jacob S. Van Naarden, Chief Bus. Officer (Age 33)
  • Ms. Sara Slifka, VP of Bus. Operations & Program Management
  • Ms. Jennifer L. Kronick, VP of HR

Who are Loxo Oncology's major shareholders?

Loxo Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc (8.72%), Vanguard Group Inc. (8.72%), BlackRock Inc. (7.45%), Aisling Capital LLC (6.69%), FMR LLC (6.27%) and OppenheimerFunds Inc. (3.32%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Institutional Ownership Trends for Loxo Oncology.

Which institutional investors are selling Loxo Oncology stock?

LOXO stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, FMR LLC, Marshall Wace North America L.P., FIL Ltd, OppenheimerFunds Inc., Morgan Stanley, Prudential Financial Inc. and Aquilo Capital Management LLC. Company insiders that have sold Loxo Oncology company stock in the last year include Aisling Capital Iii Lp, Avi Z Naider, Jennifer Burstein, Joshua H Bilenker, Lori Anne Kunkel, Naarden Jacob Van and Timothy M Mayleben. View Insider Buying and Selling for Loxo Oncology.

Which institutional investors are buying Loxo Oncology stock?

LOXO stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Vanguard Group Inc, Vanguard Group Inc., Carillon Tower Advisers Inc., Point72 Asset Management L.P., BlackRock Inc., JPMorgan Chase & Co. and JPMorgan Chase & Co.. View Insider Buying and Selling for Loxo Oncology.

How do I buy shares of Loxo Oncology?

Shares of LOXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of LOXO stock can currently be purchased for approximately $138.87.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $4.25 billion and generates $21.30 million in revenue each year. The biopharmaceutical company earns $-148,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis. Loxo Oncology employs 59 workers across the globe.

What is Loxo Oncology's official website?

The official website for Loxo Oncology is http://www.loxooncology.com.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (NASDAQ LOXO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  315 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  531
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe LOXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOXO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Featured Article: Futures Contract

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel